Drug Discovery, Delivery and Experimental Therapeutics Program

药物的发现、递送和实验治疗：摘要 药物发现，交付和实验治疗（D3 ET）研究计划整合了广泛的 一系列研究领域，有助于发现新的癌症治疗剂以及新的 有效药物输送的方法;开发用于治疗和治疗的药物产品和诊断方法， 预防癌症;以及在假设驱动的实验中评估这些医学创新 治疗试验。D3 ET是围绕三个中心，高度集成的科学主题组织的：1）药物 发现和交付; 2）药物和诊断开发;以及3）新癌症治疗的评估 实验性治疗试验中的策略。D3 ET共有62个成员，包括36个正式成员和26个准成员 成员成员反映了一系列高级和早期阶段的研究人员与27名教授，13 副教授和20名助理教授和两名关键共享资源人员。D3 ET成员 来自25个部门的儿童慈善（CM），堪萨斯大学劳伦斯分校（KU-L）， 和堪萨斯城的堪萨斯大学医学中心（KUMC），为 学科多样性和团队科学。 在报告期内（CY 20），85%的计划成员接受了与癌症相关的外部资助 研究赠款金从2016年到2020年，D3 ET计划实现了以癌症为重点的强大和不断增长的研究 portfolio. D3 ET成员在过去五年中将资金增加了一倍（增加了1500万美元），其中700万美元 增加的资金包括同行评审资金和800万美元的非同行评审资金，沿着近 增加一倍的NCI赞助的直接资助。D3 ET已经成功地推进了五种KU发明的癌症 治疗药物（见表4），临床试验在过去的四年。D3 ET计划使 在出版其研究成果方面取得了实质性进展，并增加了方案内（33%）和方案间（33%）的研究成果。 项目合作（21%）。在2016年至2020年期间，D3 ET成员发表了902篇与癌症相关的文章。 出版物（平均每位成员14.5篇出版物），包括142篇影响力大的期刊出版物 影响因子≥ 10.0（16%）。D3 ET由John A.泰勒，医学博士，硕士（KUMC），普里扬卡夏尔马， MD（KUMC）和Dan A.狄克逊，博士（KU-L），谁带来了互补的科学专业知识，在药物发现， 发展和实验疗法以及良好的指导记录。这个高度互动 领导团队每两周与翻译副总监Scott Weir，PharmD，PhD（KUMC）会面 研究，以确保与更广泛的癌症中心目标和计划的无缝集成。

DRUG DISCOVERY, DELIVERY AND EXPERIMENTAL THERAPEUTICS: ABSTRACT The Drug Discovery, Delivery and Experimental Therapeutics (D3ET) research program integrates a broad range of research areas that contribute to the discovery of new cancer therapeutic agents as well as novel approaches to effective drug delivery; the development of drug products and diagnostics for the treatment and prevention of cancer; and the evaluation of these medical innovations in hypothesis-driven experimental therapeutics trials. D3ET is organized around three central, highly integrated scientific themes: 1) Drug Discovery and Delivery; 2) Drug and Diagnostic Development; and 3) Evaluation of New Cancer Treatment Strategies in Experimental Therapeutic Trials. D3ET has 62 members, including 36 full and 26 associate members. Membership reflects a range of senior and early stage investigators with 27 Professors, 13 Associate Professors and 20 Assistant Professors and two key shared resource personnel. D3ET members are drawn from 25 departments across Children’s Mercy (CM), the University of Kansas in Lawrence (KU-L), and the University of Kansas Medical Center in Kansas City (KUMC), providing a rich environment for discipline diversity and team science. During the reporting period (CY20), 85% of program members have cancer relevant, externally funded research grants. From 2016-2020, the D3ET program achieved a strong and growing cancer-focused research portfolio. D3ET members have doubled funding (increase of $15M) over the past five years with $7M of this increase comprised of peer-reviewed funding and $8M of non-peer reviewed funding, along with a near doubling of NCI-sponsored direct funding. D3ET has successfully advanced five KU-invented cancer therapeutic agents (See Table 4), to clinical trials over the past four years. The D3ET program has made substantial progress in publishing its research and increasing intra-programmatic (33%) and inter- programmatic (21%) collaborations. Between 2016 and 2020, D3ET members published 902 cancer-relevant publications (an average of 14.5 publications per member), including 142 high-impact publications in journals with impact factors ≥ 10.0 (16%). D3ET is jointly led by John A. Taylor, MD, MS (KUMC), Priyanka Sharma, MD (KUMC), and Dan A. Dixon, PhD (KU-L), who bring complementary scientific expertise in drug discovery, development and experimental therapeutics and strong track records of mentorship. This highly interactive leadership team meets biweekly with Scott Weir, PharmD, PhD (KUMC), Associate Director for Translational Research, to ensure seamless integration with broader cancer center goals and initiatives.